Compare Eli Lilly And Co (LLY) vs McDonald's Corp (MCD) Price & Performance

Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.

LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.

McDonald's (MCD) trades at $236.9, up 2.61% today, but technical indicators signal a bearish trend. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.38 exceeding the $3.32 estimate. Revenue growth remains steady, reaching $26.89B in 2025, while net income margin stands at 31.72%. Recent news highlights the launch of the 'McDonald's NEXT' strategy focusing on automation and improved customer experience to drive growth amid competitive pressures.

The outlook for MCD is mixed: analyst consensus is bullish with a $284.70 price target, but technical weakness and inflation risks pose challenges. Investment appeal lies in its robust profitability and dividend payments, though high debt levels and margin pressures from rising costs require monitoring for sustained shareholder value.